Hormone-replacement therapy: current thinking (Q38975101)

8 September 2017

1 reference

title

Hormone-replacement therapy: current thinking (English)

1 reference

Hormone Replacement Therapy

8 September 2017

1 reference

Roger A Lobo

1

1 reference

8 September 2017

7 October 2016

1 reference

Nature Reviews Endocrinology

8 September 2017

1 reference

8 September 2017

13

1 reference

8 September 2017

220-231

1 reference

8 September 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2016.164

8 September 2017

0 references

cites work

Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Postmenopausal hormone therapy and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Estrogen therapy in postmenopausal women: effects on cognitive function and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Stroke prevention and oestrogen replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone therapy to prevent disease and prolong life in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Coronary heart disease and menopause management: the swinging pendulum of HRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Evolution of postmenopausal hormone therapy between 2002 and 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Increased Cardiovascular Mortality Risk in Women Discontinuing Postmenopausal Hormone Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Even as mortality fell in most US counties, female mortality nonetheless rose in 42.8 percent of counties from 1992 to 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Does menopausal hormone therapy reduce myocardial infarction risk if initiated early after menopause? A population-based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

MicroRNAs in the aging female brain: a putative mechanism for age-specific estrogen effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone replacement therapy and cognition: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Timing of hormone therapy and dementia: the critical window theory revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Mood disorders in midlife women: understanding the critical window and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormonal therapies for new onset and relapsed depression during perimenopause

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Recommendations for the management of postmenopausal vaginal atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

The 2012 hormone therapy position statement of: The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Thrombotic stroke and myocardial infarction with hormonal contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Estrogen receptor beta as target for colorectal cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone therapy and breast cancer risk 10 years after the WHI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

What are the real risks for breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Increased Risk of Endometrial Carcinoma among Users of Conjugated Estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Endometrial cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Postmenopausal hormone therapy: an Endocrine Society scientific statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

The cost-effectiveness of hormone therapy in younger and older postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

2016 IMS Recommendations on women's midlife health and menopause hormone therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Algorithm and mobile app for menopausal symptom management and hormonal/non-hormonal therapy decision making: a clinical decision-support tool from The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Prevention of diseases after menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Drug treatment of hyperlipidemia in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Where are we 10 years after the Women's Health Initiative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Molecular and cellular basis of cardiovascular gender differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Menopausal hormone therapy—ovarian cancer risk revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Reproductive endocrinology: Don't be so quick to stop hormone-replacement therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Coronary Heart Disease Mortality and Hormone Therapy Before and After the Womenʼs Health Initiative

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Cochrane Database of Systematic Reviews

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Unopposed estrogen therapy and the risk of invasive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2016.164

31 March 2020

Identifiers

DOI

10.1038/NRENDO.2016.164

1 reference

8 September 2017

1 reference

PubMed ID

27716751